Under the continuous prying of volume purchasing, layoffs and sales may occur frequently

[pharmaceutical network industry news] according to foreign media, MSD recently announced that MSD will abolish about 500 positions in several states of the United States from January 3, 2020 The layoff mainly affected sales and a small number of marketing personnel It is worth mentioning that in May this year, MSD announced the manufacturing restructuring plan, which will last until 2023 At the same time, it plans to close some factories or lay off workers It can be seen that the 500 posts announced to be withdrawn by MSD this time may be the continuation of the above plan The industry believes that under the continuous prying of volume purchasing, multinational pharmaceutical companies may reduce staff and sell factories frequently On the one hand, with the promotion of volume purchasing, the new ecology of China's pharmaceutical market is being reshaped, the profit highland of the original research drugs in the domestic market is gradually lost, and the related pharmaceutical sales posts are facing a reshuffle In this context, some salesmen of multinational pharmaceutical companies may face job transfer or dismissal From the perspective of multinational pharmaceutical enterprises, due to the development of the industry and changes in the market environment, many multinational pharmaceutical enterprises will make personnel transfer In the Chinese market, for the enterprises that fail to enter the volume purchase, due to their market and revenue will be affected In order to cope with market changes, pharmaceutical enterprises need to adjust the sales team of relevant varieties, or even directly disband the sales team For example, in January this year, after BMS announced its $74 billion acquisition of new base, personnel changes were frequent According to the industry, the personnel adjustment of BMS this year is mainly to match with the new company after the acquisition of Xinji, while the personnel transfer in China is to better occupy and layout the Chinese market On the other hand, with the change of pharmaceutical market pattern, the innovative pharmaceutical track will become more crowded At present, pharmaceutical giants such as MSD, Novartis, GSK, Roche, Lilly, Pfizer and AstraZeneca are accelerating their "slimming" plans, divesting non core businesses, focusing on advantageous businesses and improving their innovation capabilities, so as to adjust and optimize the company's development strategy For example, not long ago, Novartis strategically adjusted its biomedical research center in Shanghai, shifting its focus from drug discovery to development and accelerating the development of innovative drugs Subsequently, Sanofi global also announced that it would stop developing new diabetes and cardiovascular disease drugs, and made a major strategic adjustment, that is, focusing on the change of the company's product structure, focusing on the three business units of specialty drugs, vaccines and generic drugs, while the consumer health business will become an independent business department with comprehensive R & D and production It is reported that in the Chinese market, Sanofi will choose to relocate to usher in a new stage of growth, and will try to promote the sales growth of existing products and diabetes products At the same time, it plans to obtain more drugs and create a new market pattern in China within six years Recently, it was also reported that Pfizer would close its R & D center in China, which attracted wide attention in the industry However, according to Pfizer's response to the media, the news is not true, but Pfizer has decided to stop the plan of launching the Asian discovery laboratory in the near future, and maintain the mode of seeking research funds, biotechnology cooperation and equity investment in the Asia Pacific region through Pfizer's global emerging science and innovation team In general, in the switching of pharmaceutical battlefields, pharmaceutical giants are speeding up the process of listing innovative drugs or competing for the next heavyweight drug market.